Semaglutide: A Revolution in Obesity Treatment (Case of France)
From Diabetes Treatment to Weight Loss
Semaglutide, known as Ozempic for treating type 2 diabetes, gained significant attention due to its unexpected side effect: significant weight loss. Today, it is marketed under the name Wegovy for obesity treatment, with a higher dosage. In France, it has been available since October 8, although reimbursement is still pending.
Where Does This Sudden Popularity Come From?
Social Media Plays a Big Role:
Semaglutide quickly gained popularity on social media. Originally developed to treat type 2 diabetes, it caught the attention of influencers due to its effectiveness in promoting weight loss, a result that was not initially anticipated. They recommended it for aesthetic reasons, triggering both excitement and misuse, which led to shortages.
An Effective Solution to Fight Obesity
Wegovy is not just a passing trend but a real therapeutic option for managing obesity. This medication has shown an average weight loss of 12% after 68 weeks of use, a result that was previously only achievable through bariatric surgery, an invasive procedure that alters the digestive system.
Obstacles to Accessing Wegovy in France
A Promising Medication, but at a High Cost
You need to spend between 9 and 12 euros per day for a course of semaglutide, which is not affordable for everyone, especially for those with modest incomes. Additionally, prices are set by pharmaceutical companies, making it hard to expect a significant drop in price.
A Strategic Launch, but Controversial
The introduction of Wegovy to the French market, even before the final price discussions were concluded, stirred up considerable debate. Experts believe Novo Nordisk chose this approach to stay ahead of the competition, particularly tirzepatide, a highly anticipated treatment that could soon hit the market.
Strict Criteria to Ensure Patient Safety
The French National Agency for the Safety of Medicines and Health Products (ANSM) has set clear rules for the use of Wegovy. This medication is intended for people under 65 years old with a BMI of 35 or higher, after failed dietary and physical activity interventions. Only certain specialists will be authorized to prescribe the medication, while general practitioners will monitor the patients.
New Treatment Possibilities
Current studies are not limited to the effects of semaglutide on obesity. They are also exploring its effectiveness in other areas, such as the treatment of renal failure. If the results are positive, semaglutide could be used to treat additional diseases.
A New Way to Treat Obesity
Wegovy represents a significant advancement in the treatment of obesity. However, its high cost and strict prescription conditions make it difficult for many people to access.
The Competition Is Coming
Other treatments, such as tirzepatide, are expected to arrive in the market in the coming months. But for now, Wegovy paves the way for innovative treatments, offering a new perspective for patients with severe obesity.
